Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Inpharmatics Establishes New Business Unit Rosetta Biosoftware

NEW YORK, Sept. 20 – Merck's wholly owned subsidiary Rosetta Inpharmatics said Thursday it had established a new business unit, Rosetta Biosoftware, to develop and sell new bioinformatics software for life science research.

The new business unit, which will be based in Kirkland, Wash., will continue to develop new versions of Rosetta’s flagship product, the Rosetta Resolver Gene Expression Data Analysis System.

Agilent Technologies will remain the exclusive distributor of Rosetta software.

Douglas Bassett, formerly senior director of biosoftware products and services at Rosetta Inpharmatics, will be the general manager of the new business unit, which will initially have 50 employees.

"Rosetta Biosoftware's mission is to create best-of-breed bioinformatics software solutions for life science research," Bassett said in a statement. "In the tradition of the Rosetta Resolver system, we will develop pioneering solutions that enable research in gene expression, proteomics, and other areas of discovery."

Rosetta Inpharmatics will continue to develop genomic technologies for drug discovery. The company focuses on how medical compounds affect biology.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.